Zai Lab Limited (ZLAB) is currently priced at $27.06, with a price change of 39 cents representing a 1.46% increase from the previous close at $26.67. The trading volume is significantly higher, standing at $3.94 million, a 485.39% increase relative to the average.
During the latest quarterly earnings release on Monday, November 11th, ZLAB experienced a price change of $-4.03, a 12.96% decrease. The consensus estimate EPS was -0.78 for the third quarter of 2024. The latest quarterly revenue consensus estimate was $102.24 million.
Key financial ratios for ZLAB include a quick ratio of 3.29, cash ratio of 2.9, and a gross profit margin of 64.94%. The operating profit margin is -75.68%, with a net profit margin also at -79.87%. Return on assets and return on equity stand at -8.13% and -11.4% respectively. The debt ratio is 8.48, while the debt equity ratio is 11.88. ZLAB's price to book ratio is 2.4, and the price to sales ratio is 16.79.
In summary, Zai Lab Limited (ZLAB) has shown positive price movement in the current session, with notable trading volume. However, the earnings report indicated a decrease in price and challenging profit margins. The financial ratios provide a comprehensive view of the company's performance metrics. Investors should monitor these factors closely to make informed decisions regarding ZLAB.
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.